Simultaneous Onset of Haematological Malignancy and COVID: An Epicovideha Survey

Chiara Cattaneo; Jon Salmanton-García; Francesco Marchesi; Shaimaa El-Ashwah; Federico Itri; Barbora Weinbergerová; Maria Gomes Da Silva; Michelina Dargenio; Julio Dávila-Valls; Sonia Martín-Pérez; Francesca Farina; Jaap Van Doesum; Toni Valković; Caroline Besson; Christian Bjørn Poulsen; Alberto López-García; Pavel Žák; Martin Schönlein; Klára Piukovics; Ozren Jaksic; Alba Cabirta; Natasha Ali; Uluhan Sili; Nicola Fracchiolla; Giulia Dragonetti; Tatjana Adžić-Vukičević; Monia Marchetti; Marina Machado; Andreas Glenthøj; Olimpia Finizio; Fatih Demirkan; Ola Blennow; Maria Chiara Tisi; Ali S. Omrani; Milan Navrátil; Zdeněk Ráčil; Jan Novák; Gabriele Magliano; Moraima Jiménez; Carolina Garcia-Vidal; Nurettin Erben; Maria Ilaria Del Principe; Caterina Buquicchio; Rui Bergantim; Josip Batinić; Murtadha Al-Khabori; Luisa Verga; Tomáš Szotkowski; Michail Samarkos; Irati Ormazabal-Vélez; Stef Meers; Johan Maertens; László Imre Pinczés; Martin Hoenigl; Ľuboš Drgoňa; Annarosa Cuccaro; Yavuz M. Bilgin; Avinash Aujayeb; Laman Rahimli; Stefanie Gräfe; Mariarita Sciumè; Miloš Mladenović; Gökçe Melis Çolak; Maria Vittoria Sacchi; Anna Nordlander; Caroline Berg Venemyr; Michaela Hanáková; Nicole García-Poutón; Ziad Emarah; Giovanni Paolo Maria Zambrotta; Raquel Nunes Rodrigues; Raul Cordoba; Gustavo-Adolfo Méndez; Monika M. Biernat; Oliver A. Cornely; Livio Pagano

doi:10.3390/cancers14225530

Simultaneous Onset of Haematological Malignancy and COVID: An Epicovideha Survey

Chiara Cattaneo, Jon Salmanton-García, Francesco Marchesi, Shaimaa El-Ashwah, Federico Itri, Barbora Weinbergerová, Maria Gomes Da Silva, Michelina Dargenio, Julio Dávila-Valls, Sonia Martín-Pérez, Francesca Farina, Jaap Van Doesum, Toni Valković, Caroline Besson, Christian Bjørn Poulsen, Alberto López-García, Pavel Žák, Martin Schönlein, Klára Piukovics, Ozren JaksicAlba Cabirta, Natasha Ali, Uluhan Sili, Nicola Fracchiolla, Giulia Dragonetti, Tatjana Adžić-Vukičević, Monia Marchetti, Marina Machado, Andreas Glenthøj, Olimpia Finizio, Fatih Demirkan, Ola Blennow, Maria Chiara Tisi, Ali S. Omrani, Milan Navrátil, Zdeněk Ráčil, Jan Novák, Gabriele Magliano, Moraima Jiménez, Carolina Garcia-Vidal, Nurettin Erben, Maria Ilaria Del Principe, Caterina Buquicchio, Rui Bergantim, Josip Batinić, Murtadha Al-Khabori, Luisa Verga, Tomáš Szotkowski, Michail Samarkos, Irati Ormazabal-Vélez, Stef Meers, Johan Maertens, László Imre Pinczés, Martin Hoenigl, Ľuboš Drgoňa, Annarosa Cuccaro, Yavuz M. Bilgin, Avinash Aujayeb, Laman Rahimli, Stefanie Gräfe, Mariarita Sciumè, Miloš Mladenović, Gökçe Melis Çolak, Maria Vittoria Sacchi, Anna Nordlander, Caroline Berg Venemyr, Michaela Hanáková, Nicole García-Poutón, Ziad Emarah, Giovanni Paolo Maria Zambrotta, Raquel Nunes Rodrigues, Raul Cordoba, Gustavo-Adolfo Méndez, Monika M. Biernat, Oliver A. Cornely, Livio Pagano

Risultato della ricerca: Contributo in rivista › Articolo in rivista

Abstract

Background: The outcome of patients with simultaneous diagnosis of haematological malignancies (HM) and COVID-19 is unknown and there are no specific treatment guidelines. Methods: We describe the clinical features and outcome of a cohort of 450 patients with simultaneous diagnosis of HM and COVID-19 registered in the EPICOVIDEHA registry between March 2020 to February 2022. Results: Acute leukaemia and lymphoma were the most frequent HM (35.8% and 35.1%, respectively). Overall, 343 (76.2%) patients received treatment for HM, which was delayed for longer than one month since diagnosis in 57 (16.6%). An overall response rate was observed in 140 (40.8%) patients after the first line of treatment. After a median follow-up of 35 days, overall mortality was 177/450 (39.3%); 30-day mortality was significantly higher in patients not receiving HM treatment (42.1%) than in those receiving treatment (27.4%, p = 0.004), either before and/or after COVID-19, or compared to patients receiving HM treatment at least after COVID-19 (15.2%, p < 0.001). Age, severe/critical COVID-19, ≥2 comorbidities, and lack of HM treatment were independent risk factors for mortality, whereas a lymphocyte count >500/mcl at COVID-19 onset was protective. Conclusions: HM treatment should be delivered as soon as possible for patients with simultaneous diagnosis of COVID-19 and HM requiring immediate therapy.

Lingua originale	English
pagine (da-a)	5530-5538
Numero di pagine	9
Rivista	Cancers
Volume	14
DOI	https://doi.org/10.3390/cancers14225530
Stato di pubblicazione	Pubblicato - 2022

Keywords

COVID-19
haematological malignancy onset
outcome
prognostic factors
treatment

Accesso al documento

10.3390/cancers14225530

Altri file e collegamenti

Link a IRIS PubliCatt

Cita questo

Cattaneo, C., Salmanton-García, J., Marchesi, F., El-Ashwah, S., Itri, F., Weinbergerová, B., Gomes Da Silva, M., Dargenio, M., Dávila-Valls, J., Martín-Pérez, S., Farina, F., Van Doesum, J., Valković, T., Besson, C., Poulsen, C. B., López-García, A., Žák, P., Schönlein, M., Piukovics, K., ... Pagano, L. (2022). Simultaneous Onset of Haematological Malignancy and COVID: An Epicovideha Survey. Cancers, 14, 5530-5538. https://doi.org/10.3390/cancers14225530

@article{b525df11d8574b1e8c12beef8e8de9d7,

title = "Simultaneous Onset of Haematological Malignancy and COVID: An Epicovideha Survey",

abstract = "Background: The outcome of patients with simultaneous diagnosis of haematological malignancies (HM) and COVID-19 is unknown and there are no specific treatment guidelines. Methods: We describe the clinical features and outcome of a cohort of 450 patients with simultaneous diagnosis of HM and COVID-19 registered in the EPICOVIDEHA registry between March 2020 to February 2022. Results: Acute leukaemia and lymphoma were the most frequent HM (35.8% and 35.1%, respectively). Overall, 343 (76.2%) patients received treatment for HM, which was delayed for longer than one month since diagnosis in 57 (16.6%). An overall response rate was observed in 140 (40.8%) patients after the first line of treatment. After a median follow-up of 35 days, overall mortality was 177/450 (39.3%); 30-day mortality was significantly higher in patients not receiving HM treatment (42.1%) than in those receiving treatment (27.4%, p = 0.004), either before and/or after COVID-19, or compared to patients receiving HM treatment at least after COVID-19 (15.2%, p < 0.001). Age, severe/critical COVID-19, ≥2 comorbidities, and lack of HM treatment were independent risk factors for mortality, whereas a lymphocyte count >500/mcl at COVID-19 onset was protective. Conclusions: HM treatment should be delivered as soon as possible for patients with simultaneous diagnosis of COVID-19 and HM requiring immediate therapy.",

keywords = "COVID-19, haematological malignancy onset, outcome, prognostic factors, treatment, COVID-19, haematological malignancy onset, outcome, prognostic factors, treatment",

author = "Chiara Cattaneo and Jon Salmanton-Garc{\'i}a and Francesco Marchesi and Shaimaa El-Ashwah and Federico Itri and Barbora Weinbergerov{\'a} and {Gomes Da Silva}, Maria and Michelina Dargenio and Julio D{\'a}vila-Valls and Sonia Mart{\'i}n-P{\'e}rez and Francesca Farina and {Van Doesum}, Jaap and Toni Valkovi{\'c} and Caroline Besson and Poulsen, {Christian Bj{\o}rn} and Alberto L{\'o}pez-Garc{\'i}a and Pavel {\v Z}{\'a}k and Martin Sch{\"o}nlein and Kl{\'a}ra Piukovics and Ozren Jaksic and Alba Cabirta and Natasha Ali and Uluhan Sili and Nicola Fracchiolla and Giulia Dragonetti and Tatjana Ad{\v z}i{\'c}-Vuki{\v c}evi{\'c} and Monia Marchetti and Marina Machado and Andreas Glenth{\o}j and Olimpia Finizio and Fatih Demirkan and Ola Blennow and Tisi, {Maria Chiara} and Omrani, {Ali S.} and Milan Navr{\'a}til and Zden{\v e}k R{\'a}{\v c}il and Jan Nov{\'a}k and Gabriele Magliano and Moraima Jim{\'e}nez and Carolina Garcia-Vidal and Nurettin Erben and {Del Principe}, {Maria Ilaria} and Caterina Buquicchio and Rui Bergantim and Josip Batini{\'c} and Murtadha Al-Khabori and Luisa Verga and Tom{\'a}{\v s} Szotkowski and Michail Samarkos and Irati Ormazabal-V{\'e}lez and Stef Meers and Johan Maertens and Pincz{\'e}s, {L{\'a}szl{\'o} Imre} and Martin Hoenigl and {\v L}ubo{\v s} Drgo{\v n}a and Annarosa Cuccaro and Bilgin, {Yavuz M.} and Avinash Aujayeb and Laman Rahimli and Stefanie Gr{\"a}fe and Mariarita Scium{\`e} and Milo{\v s} Mladenovi{\'c} and {\c C}olak, {G{\"o}k{\c c}e Melis} and Sacchi, {Maria Vittoria} and Anna Nordlander and {Berg Venemyr}, Caroline and Michaela Han{\'a}kov{\'a} and Nicole Garc{\'i}a-Pout{\'o}n and Ziad Emarah and Zambrotta, {Giovanni Paolo Maria} and {Nunes Rodrigues}, Raquel and Raul Cordoba and Gustavo-Adolfo M{\'e}ndez and Biernat, {Monika M.} and Cornely, {Oliver A.} and Livio Pagano",

year = "2022",

doi = "10.3390/cancers14225530",

language = "English",

volume = "14",

pages = "5530--5538",

journal = "Cancers",

issn = "2072-6694",

publisher = "Basel : MDPI",

}

Cattaneo, C, Salmanton-García, J, Marchesi, F, El-Ashwah, S, Itri, F, Weinbergerová, B, Gomes Da Silva, M, Dargenio, M, Dávila-Valls, J, Martín-Pérez, S, Farina, F, Van Doesum, J, Valković, T, Besson, C, Poulsen, CB, López-García, A, Žák, P, Schönlein, M, Piukovics, K, Jaksic, O, Cabirta, A, Ali, N, Sili, U, Fracchiolla, N, Dragonetti, G, Adžić-Vukičević, T, Marchetti, M, Machado, M, Glenthøj, A, Finizio, O, Demirkan, F, Blennow, O, Tisi, MC, Omrani, AS, Navrátil, M, Ráčil, Z, Novák, J, Magliano, G, Jiménez, M, Garcia-Vidal, C, Erben, N, Del Principe, MI, Buquicchio, C, Bergantim, R, Batinić, J, Al-Khabori, M, Verga, L, Szotkowski, T, Samarkos, M, Ormazabal-Vélez, I, Meers, S, Maertens, J, Pinczés, LI, Hoenigl, M, Drgoňa, Ľ, Cuccaro, A, Bilgin, YM, Aujayeb, A, Rahimli, L, Gräfe, S, Sciumè, M, Mladenović, M, Çolak, GM, Sacchi, MV, Nordlander, A, Berg Venemyr, C, Hanáková, M, García-Poutón, N, Emarah, Z, Zambrotta, GPM, Nunes Rodrigues, R, Cordoba, R, Méndez, G-A, Biernat, MM, Cornely, OA & Pagano, L 2022, 'Simultaneous Onset of Haematological Malignancy and COVID: An Epicovideha Survey', Cancers, vol. 14, pagg. 5530-5538. https://doi.org/10.3390/cancers14225530

TY - JOUR

T1 - Simultaneous Onset of Haematological Malignancy and COVID: An Epicovideha Survey

AU - Cattaneo, Chiara

AU - Salmanton-García, Jon

AU - Marchesi, Francesco

AU - El-Ashwah, Shaimaa

AU - Itri, Federico

AU - Weinbergerová, Barbora

AU - Gomes Da Silva, Maria

AU - Dargenio, Michelina

AU - Dávila-Valls, Julio

AU - Martín-Pérez, Sonia

AU - Farina, Francesca

AU - Van Doesum, Jaap

AU - Valković, Toni

AU - Besson, Caroline

AU - Poulsen, Christian Bjørn

AU - López-García, Alberto

AU - Žák, Pavel

AU - Schönlein, Martin

AU - Piukovics, Klára

AU - Jaksic, Ozren

AU - Cabirta, Alba

AU - Ali, Natasha

AU - Sili, Uluhan

AU - Fracchiolla, Nicola

AU - Dragonetti, Giulia

AU - Adžić-Vukičević, Tatjana

AU - Marchetti, Monia

AU - Machado, Marina

AU - Glenthøj, Andreas

AU - Finizio, Olimpia

AU - Demirkan, Fatih

AU - Blennow, Ola

AU - Tisi, Maria Chiara

AU - Omrani, Ali S.

AU - Navrátil, Milan

AU - Ráčil, Zdeněk

AU - Novák, Jan

AU - Magliano, Gabriele

AU - Jiménez, Moraima

AU - Garcia-Vidal, Carolina

AU - Erben, Nurettin

AU - Del Principe, Maria Ilaria

AU - Buquicchio, Caterina

AU - Bergantim, Rui

AU - Batinić, Josip

AU - Al-Khabori, Murtadha

AU - Verga, Luisa

AU - Szotkowski, Tomáš

AU - Samarkos, Michail

AU - Ormazabal-Vélez, Irati

AU - Meers, Stef

AU - Maertens, Johan

AU - Pinczés, László Imre

AU - Hoenigl, Martin

AU - Drgoňa, Ľuboš

AU - Cuccaro, Annarosa

AU - Bilgin, Yavuz M.

AU - Aujayeb, Avinash

AU - Rahimli, Laman

AU - Gräfe, Stefanie

AU - Sciumè, Mariarita

AU - Mladenović, Miloš

AU - Çolak, Gökçe Melis

AU - Sacchi, Maria Vittoria

AU - Nordlander, Anna

AU - Berg Venemyr, Caroline

AU - Hanáková, Michaela

AU - García-Poutón, Nicole

AU - Emarah, Ziad

AU - Zambrotta, Giovanni Paolo Maria

AU - Nunes Rodrigues, Raquel

AU - Cordoba, Raul

AU - Méndez, Gustavo-Adolfo

AU - Biernat, Monika M.

AU - Cornely, Oliver A.

AU - Pagano, Livio

PY - 2022

Y1 - 2022

N2 - Background: The outcome of patients with simultaneous diagnosis of haematological malignancies (HM) and COVID-19 is unknown and there are no specific treatment guidelines. Methods: We describe the clinical features and outcome of a cohort of 450 patients with simultaneous diagnosis of HM and COVID-19 registered in the EPICOVIDEHA registry between March 2020 to February 2022. Results: Acute leukaemia and lymphoma were the most frequent HM (35.8% and 35.1%, respectively). Overall, 343 (76.2%) patients received treatment for HM, which was delayed for longer than one month since diagnosis in 57 (16.6%). An overall response rate was observed in 140 (40.8%) patients after the first line of treatment. After a median follow-up of 35 days, overall mortality was 177/450 (39.3%); 30-day mortality was significantly higher in patients not receiving HM treatment (42.1%) than in those receiving treatment (27.4%, p = 0.004), either before and/or after COVID-19, or compared to patients receiving HM treatment at least after COVID-19 (15.2%, p < 0.001). Age, severe/critical COVID-19, ≥2 comorbidities, and lack of HM treatment were independent risk factors for mortality, whereas a lymphocyte count >500/mcl at COVID-19 onset was protective. Conclusions: HM treatment should be delivered as soon as possible for patients with simultaneous diagnosis of COVID-19 and HM requiring immediate therapy.

AB - Background: The outcome of patients with simultaneous diagnosis of haematological malignancies (HM) and COVID-19 is unknown and there are no specific treatment guidelines. Methods: We describe the clinical features and outcome of a cohort of 450 patients with simultaneous diagnosis of HM and COVID-19 registered in the EPICOVIDEHA registry between March 2020 to February 2022. Results: Acute leukaemia and lymphoma were the most frequent HM (35.8% and 35.1%, respectively). Overall, 343 (76.2%) patients received treatment for HM, which was delayed for longer than one month since diagnosis in 57 (16.6%). An overall response rate was observed in 140 (40.8%) patients after the first line of treatment. After a median follow-up of 35 days, overall mortality was 177/450 (39.3%); 30-day mortality was significantly higher in patients not receiving HM treatment (42.1%) than in those receiving treatment (27.4%, p = 0.004), either before and/or after COVID-19, or compared to patients receiving HM treatment at least after COVID-19 (15.2%, p < 0.001). Age, severe/critical COVID-19, ≥2 comorbidities, and lack of HM treatment were independent risk factors for mortality, whereas a lymphocyte count >500/mcl at COVID-19 onset was protective. Conclusions: HM treatment should be delivered as soon as possible for patients with simultaneous diagnosis of COVID-19 and HM requiring immediate therapy.

KW - COVID-19

KW - haematological malignancy onset

KW - outcome

KW - prognostic factors

KW - treatment

KW - COVID-19

KW - haematological malignancy onset

KW - outcome

KW - prognostic factors

KW - treatment

UR - http://hdl.handle.net/10807/223847

U2 - 10.3390/cancers14225530

DO - 10.3390/cancers14225530

M3 - Article

SN - 2072-6694

VL - 14

SP - 5530

EP - 5538

JO - Cancers

JF - Cancers

ER -

Simultaneous Onset of Haematological Malignancy and COVID: An Epicovideha Survey

Abstract

Keywords

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo